Advanced

Ny strategi vid typ 2-diabetes prövas i kliniska studier. Glukagonlik peptid 1 (GLP-1) påverkar sjukdomens grundorsaker

Ahrén, Bo LU (2005) In Läkartidningen 102(8). p.9-545
Abstract (Swedish)
GLP-1 (glukagonlik peptid 1) är ett inkretinhormon

som frisätts vid varje måltid.

GLP-1 stimulerar insulinsekretionen, hämmar glukagonsekretionen,

förlångsammar ventrikeltömningen

och ger mättnadskänsla.

Sammantaget har GLP-1 en glukossänkande effekt.

GLP-1 sänker blodglukos och HbA1c när det ges till patienter

med typ 2-diabetes. Risken för hypoglykemi är

mycket liten.

GLP-1 bryts snabbt och effektivt ned av enzymet dipeptidylpeptidas

4 (DPP-4); halveringstiden för hormonet

är <2 minuter.

Två strategier har utvecklats för att kliniskt kunna utnyttja

den goda effekten av GLP-1: dels GLP-1-receptoragonister

som... (More)
GLP-1 (glukagonlik peptid 1) är ett inkretinhormon

som frisätts vid varje måltid.

GLP-1 stimulerar insulinsekretionen, hämmar glukagonsekretionen,

förlångsammar ventrikeltömningen

och ger mättnadskänsla.

Sammantaget har GLP-1 en glukossänkande effekt.

GLP-1 sänker blodglukos och HbA1c när det ges till patienter

med typ 2-diabetes. Risken för hypoglykemi är

mycket liten.

GLP-1 bryts snabbt och effektivt ned av enzymet dipeptidylpeptidas

4 (DPP-4); halveringstiden för hormonet

är <2 minuter.

Två strategier har utvecklats för att kliniskt kunna utnyttja

den goda effekten av GLP-1: dels GLP-1-receptoragonister

som har lång halveringstid genom att

vara resistenta mot DPP-4, dels DPP-4-hämmare som

leder till förlängning av halveringstiden av endogent

frisatt GLP-1.

Substanser utvecklade ur båda dessa strategier är idag

föremål för kliniska studier på fas 3-nivå. (Less)
Abstract
A novel therapy for type 2 diabetes is based on the gut hormone, glucagon-like peptide-1 (GLP-1). GLP-1 is released from the gut during a meal intake and stimulates insulin secretion. The hormone also inhibits glucagon secretion, delays gastric emptying and induces satiety. It has been shown to reduce circulating glucose both under fasting conditions and after meal intake in subjects with type 2 diabetes. A problem in developing this novel therapy is that GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which results in a short half-life of the hormone requiring continuous infusion. Two strategies have been developed to circumvent this drawback. One strategy is the use of DPP-4 resistant GLP-1 receptor agonists... (More)
A novel therapy for type 2 diabetes is based on the gut hormone, glucagon-like peptide-1 (GLP-1). GLP-1 is released from the gut during a meal intake and stimulates insulin secretion. The hormone also inhibits glucagon secretion, delays gastric emptying and induces satiety. It has been shown to reduce circulating glucose both under fasting conditions and after meal intake in subjects with type 2 diabetes. A problem in developing this novel therapy is that GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which results in a short half-life of the hormone requiring continuous infusion. Two strategies have been developed to circumvent this drawback. One strategy is the use of DPP-4 resistant GLP-1 receptor agonists (exenatide and liraglutide) and another strategy is to inhibit DPP-4 activity (LAF237). Both these strategies have been successful in clinical studies. (Less)
Please use this url to cite or link to this publication:
author
organization
alternative title
New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Dipeptidyl Peptidases: antagonists & inhibitors, Type 2: drug therapy, Hypoglycemic Agents: therapeutic use, Humans, Glucagon: therapeutic use, English Abstract, Insulin: cretion, Peptide Fragments: therapeutic use, Protein Precursors: therapeutic use, Receptors, Animals, Biomedical Research, Diabetes Mellitus, Glucagon: tagonists & inhibitors, Research, Serine Proteinase Inhibitors: therapeutic use
in
Läkartidningen
volume
102
issue
8
pages
9 - 545
external identifiers
  • pmid:15786905
  • scopus:15244358950
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
fa51b848-52ce-445c-9921-45dd4e6917a3 (old id 134811)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15786905&dopt=Abstract
http://ltarkiv.lakartidningen.se/artNo29842
date added to LUP
2007-07-23 15:26:00
date last changed
2017-01-01 06:52:41
@article{fa51b848-52ce-445c-9921-45dd4e6917a3,
  abstract     = {A novel therapy for type 2 diabetes is based on the gut hormone, glucagon-like peptide-1 (GLP-1). GLP-1 is released from the gut during a meal intake and stimulates insulin secretion. The hormone also inhibits glucagon secretion, delays gastric emptying and induces satiety. It has been shown to reduce circulating glucose both under fasting conditions and after meal intake in subjects with type 2 diabetes. A problem in developing this novel therapy is that GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which results in a short half-life of the hormone requiring continuous infusion. Two strategies have been developed to circumvent this drawback. One strategy is the use of DPP-4 resistant GLP-1 receptor agonists (exenatide and liraglutide) and another strategy is to inhibit DPP-4 activity (LAF237). Both these strategies have been successful in clinical studies.},
  author       = {Ahrén, Bo},
  issn         = {0023-7205},
  keyword      = {Dipeptidyl Peptidases: antagonists & inhibitors,Type 2: drug therapy,Hypoglycemic Agents: therapeutic use,Humans,Glucagon: therapeutic use,English Abstract,Insulin: cretion,Peptide Fragments: therapeutic use,Protein Precursors: therapeutic use,Receptors,Animals,Biomedical Research,Diabetes Mellitus,Glucagon: tagonists & inhibitors,Research,Serine Proteinase Inhibitors: therapeutic use},
  language     = {swe},
  number       = {8},
  pages        = {9--545},
  series       = {Läkartidningen},
  title        = {Ny strategi vid typ 2-diabetes prövas i kliniska studier. Glukagonlik peptid 1 (GLP-1) påverkar sjukdomens grundorsaker},
  volume       = {102},
  year         = {2005},
}